1 |
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., James, D., Howard, Z., Dudley, P., Hughes, G., Smith, L., Maguire, S., Hummersone, M., Malagu, K., Menear, K., Jenkins, R., Jacobsen, M., Smith, G. C., Guichard, S. and Pass, M. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288-298.
DOI
|
2 |
Dees, E. C., Baker, S. D., O'Reilly, S., Rudek, M. A., Davidson, S. B., Aylesworth, C., Elza-Brown, K., Carducci, M. A. and Donehower, R. C. (2005) A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin. Cancer Res. 11, 664-671.
|
3 |
Granville, C. A., Memmott, R. M., Gills, J. J. and Dennis, P. A. (2006) Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 12, 679-689.
DOI
ScienceOn
|
4 |
Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A. and Roy, K. K. (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther. 2, 1093-1103.
|
5 |
Ma, W. W. and Jimeno, A. (2007) Temsirolimus. Drugs Today 43, 659-669.
DOI
ScienceOn
|
6 |
O'Donnell, A., Faivre, S. and Judson, I. (2003) A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc. Am. Soc. Clin. Oncol. 22, 803.
|
7 |
Sausville, E. A., Arbuck, S. G. and Messmann, R. (2001) Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractoryneoplasms. J. Clin. Oncol. 19, 2319-2333.
DOI
|
8 |
Koh, P. O. (2010) Gingko biloba extract (EGb 761) prevents cerebral ischemia-induced p70S6 kinase and S6 phosphorylation. Am. J. Chin. Med. 38, 727-734.
DOI
ScienceOn
|
9 |
Shi, G. D., OuYang, Y. P., Shi, J. G., Liu, Y., Yuan, W. and Jia, L. S. (2011) PTEN deletion prevents ischemic brain injury by activating the mTOR signaling pathway. Biochem. Biophys. Res. Commun. 404, 941-945.
DOI
ScienceOn
|
10 |
Huang, C. Y., Hsiao, J. K., Lu, Y. Z., Lee, T. C. and Yu, L. C. (2011) Anti-apoptotic PI3K/Akt signaling by sodium/ glucose transporter 1 reduces epithelial barrier damage and bacterial translocation in intestinal ischemia. Lab Invest. 91, 294-309.
DOI
ScienceOn
|
11 |
Zhang, Y. and Ren, J. (2010) Autophagy in ALDH2- elicited cardioprotection against ischemic heart disease: slayer or savior? Autophagy. 6, 1212-1213.
DOI
|
12 |
Zhang, L., Yang, Y., Wang, Y. and Gao, X. (2011) Astragalus membranaceus extract promotes neovascularisation by VEGF pathway in rat model of ischemic injury. Pharmazie. 66, 144-150.
|
13 |
Vigneron, F., Dos, S. P., Lemoine, S., Bonnet, M., Tariosse, L., Couffinhal, T., Duplaa, C. and Jaspard, -V. B. (2011) GSK-3 at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovasc Res. 90, 49-56.
DOI
ScienceOn
|
14 |
Chong, Z. Z., Shang, Y. C., Zhang, L., Wang, S. and Maiese, K. (2010) Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid. Med. Cell. Longev. 3, 374-391.
DOI
|
15 |
Shang, J., Deguchi, K., Yamashita, T., Ohta, Y., Zhang, H., Morimoto, N., Liu, N., Zhang, X., Tian, F., Matsuura, T., Funakoshi, H., Nakamura, T. and Abe, K. (2010) Antiapoptotic and antiautophagic effects of glial cell line-derived neurotrophic factor and hepatocyte growth factor after transient middle cerebral artery occlusion in rats. J. Neurosci Res. 88, 2197-2206.
DOI
ScienceOn
|
16 |
Ma, H., Guo, R., Yu, L., Zhang, Y. and Ren, J. (2011) Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischemia/reperfusion injury: role of autophagy paradox and toxic aldehyde. Eur. Heart J. 32, 1025-1038.
DOI
ScienceOn
|
17 |
Vezina, C., Kudelski, A. and Sehgal, S. N. (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. J. Antibiot. 28, 721-726.
DOI
|
18 |
Hein, S., Arnon, E., Kostin, S., Schonburg, M., Elsasser, A., Polyakova, V., Bauer, E. P., Klovekorn, W. P. and Schaper, J. (2003) Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107, 984-991.
DOI
ScienceOn
|
19 |
Lekli, I., Ray, D., Mukherjee, S., Gurusamy, N., Ahsan, M. K., Juhasz, B., Bak, I., Tosaki, A., Gherghiceanu, M., Popescu, L. M. and Das, D. K. (2010) Co-ordinated autophagy with resveratrol and γ-tocotrienol confers synergetic cardioprotection. J. Cell Mol. Med. 14, 2506-2518.
DOI
ScienceOn
|
20 |
Zhang, Z., Yu, B. and Tao, G. Z. (2009) Apelin protects against cardiomyocyte apoptosis induced by glucose deprivation. Chin. Med. J. (Engl). 122, 2360-2365.
|
21 |
Gurusamy, N., Lekli, I., Mukherjee, S., Ray, D., Ahsan, M. K., Gherghiceanu, M., Popescu, L. M., Das, D. K. (2010) Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc. Res. 86, 103-112.
DOI
ScienceOn
|
22 |
Trotman, L. C., Alimonti, A., Scaglioni, P. P., Koutcher, J. A., Cordon, C. C. and Pandolfi, P. P. (2006) Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441, 523-527.
DOI
ScienceOn
|
23 |
Ayuso, M. I., Hernandez, J. M., Martin, M. E., Salinas, M. and Alcazar, A. (2010) New hierarchical phosphorylation pathway of the translational repressor elF4E-binding protein 1 (4E-BP1) in ischemia-reperfusion stress. J. Biol. Chem. 285, 34355-34363.
DOI
ScienceOn
|
24 |
Oudit, G. Y. and Penninger, J. M. (2009) Cardiac Regulation by Phosphoinositide 3-kinases and PTEN. Cardiovasc. Res. 250-260.
|
25 |
Koh, P. O. (2008) Melatonin prevents ischemic brain injury through activation of the mTOR/p70S6 kinase signaling pathway. Neurosci. Lett. 444, 74-78.
DOI
ScienceOn
|
26 |
Balasubramanian, S., Johnston, R. K., Moschella, P. C., Mani, S. K., Tuxworth, W. J., Jr. and Kuppuswamy, D. (2009) mTOR in growth and protection of hypertrophying myocardium. Cardiovasc. Hematol. Agents Med. Chem. 7, 52-63.
DOI
|
27 |
Jonassen, A. K., Sack, M. N., Mjos, O. D. and Yellon, D. M. (2001) Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cellsurvival signaling. Circ. Res. 89, 1191-1198.
DOI
ScienceOn
|
28 |
Lyons, W. E., George, E. B., Dawson, T. M., Steiner, J. P. and Snyder, S. H. (1994) Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory gangli. Proc. Natl. Acad. Sci. U.S.A. 91, 3191-3195.
DOI
ScienceOn
|
29 |
Steiner, J. P., Connolly, M. A., Valentine, H. L., Hamilton, G. S., Dawson, T. M., Hester, L. and Snyder, S. H. (1997) Neurotropic actions of nonimmuosuppressive analogues of immunosuppressive drugs FK506, rapamycin, and cyclosporine A. Nat. Med. 3, 421-428.
DOI
ScienceOn
|
30 |
Erlich, S., Alexandrovich, A., Shohami, E. and Pinkas K. R. (2007) Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol. Dis. 26, 86-93.
DOI
ScienceOn
|
31 |
Ruan, B., Pong, K., Jow, F., Bowlby, M., Crozier, R. A., Liu, D., Liang, S., Chen, Y., Mercado, M. L., Feng, X., Bennett, F., von, S. D., McDonald, L., Zeleska, M. M., Wood, A., Reinhart, P. H., Magolda, R. L., Skotnicki, J., Pangalos, M. N., Koehn, F. E. Carter, G. T., Abou, G. M. and Graziani, E. l. (2008) Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc. Natl. Acad. Sci. U.S.A. 105, 33-38.
DOI
ScienceOn
|
32 |
Huang, J., Dibble, C. C., Matsuzaki, M. and Manning, B. D. (2008) The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell Biol. 28, 4104-4115.
DOI
ScienceOn
|
33 |
Carloni, S., Girelli, S., Scopa, C., Buonocore, G., Longini, M. and Balduini, W. (2010) Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia. Autophagy. 6, 366-377.
DOI
|
34 |
Hanada, M., Feng, J. and Hemmings, B. A. (2004) Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim. Biophys. Acta. 1697, 3-16.
DOI
ScienceOn
|
35 |
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J. and Su, B. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137.
DOI
ScienceOn
|
36 |
Huang, J., Wu, S., Wu, C. L. and Manning, B. D. (2009) Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res. 69, 6107-6114.
|
37 |
Wullschleger, S., Loewith, R. and Hall, M. N. (2006) TOR signaling in growth and metabolism. Cell 124, 471-484.
DOI
ScienceOn
|
38 |
Shen, W. H., Chen, Z., Shi, S., Chen, H., Zhu, W., Penner A., Bu, G., Li, W., Boyle, D. W., Rubart, M., Field, L. J., Abraham, R., Liechty, E. A. and Shou, W. (2008) Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function. J. Biol. Chem. 283, 13842-13849.
DOI
ScienceOn
|
39 |
Tong, H., Chen, W., Steenbergen, C. and Murphy, E. (2000) Ischemic preconditioning activates phosphatidylinositol- 3-kinase upstream of protein kinase C. Circ. Res. 87, 309-315.
DOI
ScienceOn
|
40 |
Khan, S., Salloum, F., Das, A., Xi, L., Vetrovec, G. W. and Kukreja, R. C. (2006) Rapamycin confers preconditioning- like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J. Mol. Cell Cardiol. 41, 256-264.
DOI
ScienceOn
|
41 |
Murphy, E. and Steenbergen, C. (2008) Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev. 88, 581-609.
DOI
ScienceOn
|
42 |
Tokunaga, C., Yoshino, K. and Yonezawa, K. (2004) mTOR integrates amino acid- and energy-sensing pathways. Biochem. Biophys. Res. Commun. 313, 443-446.
DOI
ScienceOn
|
43 |
Ma, X. (2009) Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307-318.
DOI
ScienceOn
|
44 |
Huang, J. and Manning, B. D. (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412, 179-190.
DOI
ScienceOn
|
45 |
Manning, B. D. and Cantley, L. C. (2007) AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
DOI
ScienceOn
|
46 |
Zhang, H., Bajraszewski, N., Wu, E., Wang, H., Moseman, A. P., Dabora, S. L., Griffin, J. D. and Kwiatkowski, D. J. (2007) PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 117, 730-738.
DOI
ScienceOn
|
47 |
Inoki, K., Li, Y., Zhu, T., Wu, J. and Guan, K. L. (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648-657.
DOI
ScienceOn
|
48 |
Kovacina, K. S., Park, G. Y., Bae, S. S., Guzzetta, A. W., Schaefer, E., Birnbaum, M. J. and Roth, R. A. (2003) Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem. 278, 10189-10194.
DOI
ScienceOn
|
49 |
Vander, H. E., Lee, S. I., Bandhakavi, S., Griffin, T. J. and Kim, D. H. (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9, 316-323.
DOI
ScienceOn
|
50 |
Huang, B. and Porter, G. (2005) Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis. Acta. Pharmacol. Sin. 26, 1253-1258.
DOI
ScienceOn
|
51 |
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A. and Sabatini, D. M. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25, 903-915.
DOI
ScienceOn
|
52 |
Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
DOI
ScienceOn
|
53 |
Wang, C. Y., Kim, H. H., Hiroi, Y., Sawada, N., Salomone, S., Benjamin, L. E., Walsh, K., Moskowitz, M. A. and Liao, J. K. (2009) Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci. Signal. 2, ra11.
DOI
ScienceOn
|
54 |
Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S. and Sabatini, D. M. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137, 873-886.
DOI
ScienceOn
|
55 |
Guertin, D. A. and Sabatini, D. M. (2007) Defining the Role of mTOR in Cancer. Cancer Cell 12, 9-22.
DOI
ScienceOn
|
56 |
Dumont, F. J., Staruch, M. J., Koprak, S. L., Melino, M. R. and Sigal, N. H. (1990) Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 144, 251-258.
|
57 |
Bhaskar, P. T. and Hay, N. (2007) The two TORCs and Akt. Dev. Cell. 12, 487-502.
DOI
ScienceOn
|
58 |
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P. and Hall, M. N. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457-468.
DOI
ScienceOn
|
59 |
Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J. and Sabatini, D. M. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11, 859-871.
DOI
ScienceOn
|